Global Prophylactic HIV Drug Market Growth 2025-2031

December 2025 | 104 pages | ID: G05761D6A497EN
LP Information

Abstracts

The global Prophylactic HIV Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

HIV is one of the leading cause of death worldwide affecting millions of people. HIV has become the chief contributor to the global burden diseases.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LP Information, Inc. (LPI) ' newest research report, the “Prophylactic HIV Drug Industry Forecast” looks at past sales and reviews total world Prophylactic HIV Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Prophylactic HIV Drug sales for 2025 through 2031. With Prophylactic HIV Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Prophylactic HIV Drug industry.

This Insight Report provides a comprehensive analysis of the global Prophylactic HIV Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Prophylactic HIV Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Prophylactic HIV Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Prophylactic HIV Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Prophylactic HIV Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Prophylactic HIV Drug market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
• Integrase Inhibitor

Segmentation by Application:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• Gilead Sciences
• Merck
• Mylan
• Cipla
• Bristol-Myers Squibb
• Roche

Key Questions Addressed in this Report

What is the 10-year outlook for the global Prophylactic HIV Drug market?

What factors are driving Prophylactic HIV Drug market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Prophylactic HIV Drug market opportunities vary by end market size?

How does Prophylactic HIV Drug break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Prophylactic HIV Drug Annual Sales 2020-2031
  2.1.2 World Current & Future Analysis for Prophylactic HIV Drug by Geographic Region, 2020, 2024 & 2031
  2.1.3 World Current & Future Analysis for Prophylactic HIV Drug by Country/Region, 2020, 2024 & 2031
2.2 Prophylactic HIV Drug Segment by Type
  2.2.1 Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
  2.2.2 Integrase Inhibitor
2.3 Prophylactic HIV Drug Sales by Type
  2.3.1 Global Prophylactic HIV Drug Sales Market Share by Type (2020-2025)
  2.3.2 Global Prophylactic HIV Drug Revenue and Market Share by Type (2020-2025)
  2.3.3 Global Prophylactic HIV Drug Sale Price by Type (2020-2025)
2.4 Prophylactic HIV Drug Segment by Application
  2.4.1 Hospital Pharmacy
  2.4.2 Retail Pharmacy
  2.4.3 Online Pharmacy
2.5 Prophylactic HIV Drug Sales by Application
  2.5.1 Global Prophylactic HIV Drug Sale Market Share by Application (2020-2025)
  2.5.2 Global Prophylactic HIV Drug Revenue and Market Share by Application (2020-2025)
  2.5.3 Global Prophylactic HIV Drug Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Prophylactic HIV Drug Breakdown Data by Company
  3.1.1 Global Prophylactic HIV Drug Annual Sales by Company (2020-2025)
  3.1.2 Global Prophylactic HIV Drug Sales Market Share by Company (2020-2025)
3.2 Global Prophylactic HIV Drug Annual Revenue by Company (2020-2025)
  3.2.1 Global Prophylactic HIV Drug Revenue by Company (2020-2025)
  3.2.2 Global Prophylactic HIV Drug Revenue Market Share by Company (2020-2025)
3.3 Global Prophylactic HIV Drug Sale Price by Company
3.4 Key Manufacturers Prophylactic HIV Drug Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Prophylactic HIV Drug Product Location Distribution
  3.4.2 Players Prophylactic HIV Drug Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR PROPHYLACTIC HIV DRUG BY GEOGRAPHIC REGION

4.1 World Historic Prophylactic HIV Drug Market Size by Geographic Region (2020-2025)
  4.1.1 Global Prophylactic HIV Drug Annual Sales by Geographic Region (2020-2025)
  4.1.2 Global Prophylactic HIV Drug Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Prophylactic HIV Drug Market Size by Country/Region (2020-2025)
  4.2.1 Global Prophylactic HIV Drug Annual Sales by Country/Region (2020-2025)
  4.2.2 Global Prophylactic HIV Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Prophylactic HIV Drug Sales Growth
4.4 APAC Prophylactic HIV Drug Sales Growth
4.5 Europe Prophylactic HIV Drug Sales Growth
4.6 Middle East & Africa Prophylactic HIV Drug Sales Growth

5 AMERICAS

5.1 Americas Prophylactic HIV Drug Sales by Country
  5.1.1 Americas Prophylactic HIV Drug Sales by Country (2020-2025)
  5.1.2 Americas Prophylactic HIV Drug Revenue by Country (2020-2025)
5.2 Americas Prophylactic HIV Drug Sales by Type (2020-2025)
5.3 Americas Prophylactic HIV Drug Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Prophylactic HIV Drug Sales by Region
  6.1.1 APAC Prophylactic HIV Drug Sales by Region (2020-2025)
  6.1.2 APAC Prophylactic HIV Drug Revenue by Region (2020-2025)
6.2 APAC Prophylactic HIV Drug Sales by Type (2020-2025)
6.3 APAC Prophylactic HIV Drug Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Prophylactic HIV Drug by Country
  7.1.1 Europe Prophylactic HIV Drug Sales by Country (2020-2025)
  7.1.2 Europe Prophylactic HIV Drug Revenue by Country (2020-2025)
7.2 Europe Prophylactic HIV Drug Sales by Type (2020-2025)
7.3 Europe Prophylactic HIV Drug Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Prophylactic HIV Drug by Country
  8.1.1 Middle East & Africa Prophylactic HIV Drug Sales by Country (2020-2025)
  8.1.2 Middle East & Africa Prophylactic HIV Drug Revenue by Country (2020-2025)
8.2 Middle East & Africa Prophylactic HIV Drug Sales by Type (2020-2025)
8.3 Middle East & Africa Prophylactic HIV Drug Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Prophylactic HIV Drug
10.3 Manufacturing Process Analysis of Prophylactic HIV Drug
10.4 Industry Chain Structure of Prophylactic HIV Drug

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Prophylactic HIV Drug Distributors
11.3 Prophylactic HIV Drug Customer

12 WORLD FORECAST REVIEW FOR PROPHYLACTIC HIV DRUG BY GEOGRAPHIC REGION

12.1 Global Prophylactic HIV Drug Market Size Forecast by Region
  12.1.1 Global Prophylactic HIV Drug Forecast by Region (2026-2031)
  12.1.2 Global Prophylactic HIV Drug Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Prophylactic HIV Drug Forecast by Type (2026-2031)
12.7 Global Prophylactic HIV Drug Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Gilead Sciences
  13.1.1 Gilead Sciences Company Information
  13.1.2 Gilead Sciences Prophylactic HIV Drug Product Portfolios and Specifications
  13.1.3 Gilead Sciences Prophylactic HIV Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.1.4 Gilead Sciences Main Business Overview
  13.1.5 Gilead Sciences Latest Developments
13.2 Merck
  13.2.1 Merck Company Information
  13.2.2 Merck Prophylactic HIV Drug Product Portfolios and Specifications
  13.2.3 Merck Prophylactic HIV Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.2.4 Merck Main Business Overview
  13.2.5 Merck Latest Developments
13.3 Mylan
  13.3.1 Mylan Company Information
  13.3.2 Mylan Prophylactic HIV Drug Product Portfolios and Specifications
  13.3.3 Mylan Prophylactic HIV Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.3.4 Mylan Main Business Overview
  13.3.5 Mylan Latest Developments
13.4 Cipla
  13.4.1 Cipla Company Information
  13.4.2 Cipla Prophylactic HIV Drug Product Portfolios and Specifications
  13.4.3 Cipla Prophylactic HIV Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.4.4 Cipla Main Business Overview
  13.4.5 Cipla Latest Developments
13.5 Bristol-Myers Squibb
  13.5.1 Bristol-Myers Squibb Company Information
  13.5.2 Bristol-Myers Squibb Prophylactic HIV Drug Product Portfolios and Specifications
  13.5.3 Bristol-Myers Squibb Prophylactic HIV Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.5.4 Bristol-Myers Squibb Main Business Overview
  13.5.5 Bristol-Myers Squibb Latest Developments
13.6 Roche
  13.6.1 Roche Company Information
  13.6.2 Roche Prophylactic HIV Drug Product Portfolios and Specifications
  13.6.3 Roche Prophylactic HIV Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.6.4 Roche Main Business Overview
  13.6.5 Roche Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Prophylactic HIV Drug Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Prophylactic HIV Drug Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
Table 4. Major Players of Integrase Inhibitor
Table 5. Global Prophylactic HIV Drug Sales by Type (2020-2025) & (K Units)
Table 6. Global Prophylactic HIV Drug Sales Market Share by Type (2020-2025)
Table 7. Global Prophylactic HIV Drug Revenue by Type (2020-2025) & ($ million)
Table 8. Global Prophylactic HIV Drug Revenue Market Share by Type (2020-2025)
Table 9. Global Prophylactic HIV Drug Sale Price by Type (2020-2025) & (USD/Unit)
Table 10. Global Prophylactic HIV Drug Sale by Application (2020-2025) & (K Units)
Table 11. Global Prophylactic HIV Drug Sale Market Share by Application (2020-2025)
Table 12. Global Prophylactic HIV Drug Revenue by Application (2020-2025) & ($ million)
Table 13. Global Prophylactic HIV Drug Revenue Market Share by Application (2020-2025)
Table 14. Global Prophylactic HIV Drug Sale Price by Application (2020-2025) & (USD/Unit)
Table 15. Global Prophylactic HIV Drug Sales by Company (2020-2025) & (K Units)
Table 16. Global Prophylactic HIV Drug Sales Market Share by Company (2020-2025)
Table 17. Global Prophylactic HIV Drug Revenue by Company (2020-2025) & ($ millions)
Table 18. Global Prophylactic HIV Drug Revenue Market Share by Company (2020-2025)
Table 19. Global Prophylactic HIV Drug Sale Price by Company (2020-2025) & (USD/Unit)
Table 20. Key Manufacturers Prophylactic HIV Drug Producing Area Distribution and Sales Area
Table 21. Players Prophylactic HIV Drug Products Offered
Table 22. Prophylactic HIV Drug Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Prophylactic HIV Drug Sales by Geographic Region (2020-2025) & (K Units)
Table 26. Global Prophylactic HIV Drug Sales Market Share Geographic Region (2020-2025)
Table 27. Global Prophylactic HIV Drug Revenue by Geographic Region (2020-2025) & ($ millions)
Table 28. Global Prophylactic HIV Drug Revenue Market Share by Geographic Region (2020-2025)
Table 29. Global Prophylactic HIV Drug Sales by Country/Region (2020-2025) & (K Units)
Table 30. Global Prophylactic HIV Drug Sales Market Share by Country/Region (2020-2025)
Table 31. Global Prophylactic HIV Drug Revenue by Country/Region (2020-2025) & ($ millions)
Table 32. Global Prophylactic HIV Drug Revenue Market Share by Country/Region (2020-2025)
Table 33. Americas Prophylactic HIV Drug Sales by Country (2020-2025) & (K Units)
Table 34. Americas Prophylactic HIV Drug Sales Market Share by Country (2020-2025)
Table 35. Americas Prophylactic HIV Drug Revenue by Country (2020-2025) & ($ millions)
Table 36. Americas Prophylactic HIV Drug Sales by Type (2020-2025) & (K Units)
Table 37. Americas Prophylactic HIV Drug Sales by Application (2020-2025) & (K Units)
Table 38. APAC Prophylactic HIV Drug Sales by Region (2020-2025) & (K Units)
Table 39. APAC Prophylactic HIV Drug Sales Market Share by Region (2020-2025)
Table 40. APAC Prophylactic HIV Drug Revenue by Region (2020-2025) & ($ millions)
Table 41. APAC Prophylactic HIV Drug Sales by Type (2020-2025) & (K Units)
Table 42. APAC Prophylactic HIV Drug Sales by Application (2020-2025) & (K Units)
Table 43. Europe Prophylactic HIV Drug Sales by Country (2020-2025) & (K Units)
Table 44. Europe Prophylactic HIV Drug Revenue by Country (2020-2025) & ($ millions)
Table 45. Europe Prophylactic HIV Drug Sales by Type (2020-2025) & (K Units)
Table 46. Europe Prophylactic HIV Drug Sales by Application (2020-2025) & (K Units)
Table 47. Middle East & Africa Prophylactic HIV Drug Sales by Country (2020-2025) & (K Units)
Table 48. Middle East & Africa Prophylactic HIV Drug Revenue Market Share by Country (2020-2025)
Table 49. Middle East & Africa Prophylactic HIV Drug Sales by Type (2020-2025) & (K Units)
Table 50. Middle East & Africa Prophylactic HIV Drug Sales by Application (2020-2025) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Prophylactic HIV Drug
Table 52. Key Market Challenges & Risks of Prophylactic HIV Drug
Table 53. Key Industry Trends of Prophylactic HIV Drug
Table 54. Prophylactic HIV Drug Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Prophylactic HIV Drug Distributors List
Table 57. Prophylactic HIV Drug Customer List
Table 58. Global Prophylactic HIV Drug Sales Forecast by Region (2026-2031) & (K Units)
Table 59. Global Prophylactic HIV Drug Revenue Forecast by Region (2026-2031) & ($ millions)
Table 60. Americas Prophylactic HIV Drug Sales Forecast by Country (2026-2031) & (K Units)
Table 61. Americas Prophylactic HIV Drug Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 62. APAC Prophylactic HIV Drug Sales Forecast by Region (2026-2031) & (K Units)
Table 63. APAC Prophylactic HIV Drug Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 64. Europe Prophylactic HIV Drug Sales Forecast by Country (2026-2031) & (K Units)
Table 65. Europe Prophylactic HIV Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 66. Middle East & Africa Prophylactic HIV Drug Sales Forecast by Country (2026-2031) & (K Units)
Table 67. Middle East & Africa Prophylactic HIV Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 68. Global Prophylactic HIV Drug Sales Forecast by Type (2026-2031) & (K Units)
Table 69. Global Prophylactic HIV Drug Revenue Forecast by Type (2026-2031) & ($ millions)
Table 70. Global Prophylactic HIV Drug Sales Forecast by Application (2026-2031) & (K Units)
Table 71. Global Prophylactic HIV Drug Revenue Forecast by Application (2026-2031) & ($ millions)
Table 72. Gilead Sciences Basic Information, Prophylactic HIV Drug Manufacturing Base, Sales Area and Its Competitors
Table 73. Gilead Sciences Prophylactic HIV Drug Product Portfolios and Specifications
Table 74. Gilead Sciences Prophylactic HIV Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 75. Gilead Sciences Main Business
Table 76. Gilead Sciences Latest Developments
Table 77. Merck Basic Information, Prophylactic HIV Drug Manufacturing Base, Sales Area and Its Competitors
Table 78. Merck Prophylactic HIV Drug Product Portfolios and Specifications
Table 79. Merck Prophylactic HIV Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 80. Merck Main Business
Table 81. Merck Latest Developments
Table 82. Mylan Basic Information, Prophylactic HIV Drug Manufacturing Base, Sales Area and Its Competitors
Table 83. Mylan Prophylactic HIV Drug Product Portfolios and Specifications
Table 84. Mylan Prophylactic HIV Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 85. Mylan Main Business
Table 86. Mylan Latest Developments
Table 87. Cipla Basic Information, Prophylactic HIV Drug Manufacturing Base, Sales Area and Its Competitors
Table 88. Cipla Prophylactic HIV Drug Product Portfolios and Specifications
Table 89. Cipla Prophylactic HIV Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 90. Cipla Main Business
Table 91. Cipla Latest Developments
Table 92. Bristol-Myers Squibb Basic Information, Prophylactic HIV Drug Manufacturing Base, Sales Area and Its Competitors
Table 93. Bristol-Myers Squibb Prophylactic HIV Drug Product Portfolios and Specifications
Table 94. Bristol-Myers Squibb Prophylactic HIV Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 95. Bristol-Myers Squibb Main Business
Table 96. Bristol-Myers Squibb Latest Developments
Table 97. Roche Basic Information, Prophylactic HIV Drug Manufacturing Base, Sales Area and Its Competitors
Table 98. Roche Prophylactic HIV Drug Product Portfolios and Specifications
Table 99. Roche Prophylactic HIV Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 100. Roche Main Business
Table 101. Roche Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Prophylactic HIV Drug
Figure 2. Prophylactic HIV Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Prophylactic HIV Drug Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Prophylactic HIV Drug Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Prophylactic HIV Drug Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Prophylactic HIV Drug Sales Market Share by Country/Region (2024)
Figure 10. Prophylactic HIV Drug Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
Figure 12. Product Picture of Integrase Inhibitor
Figure 13. Global Prophylactic HIV Drug Sales Market Share by Type in 2025
Figure 14. Global Prophylactic HIV Drug Revenue Market Share by Type (2020-2025)
Figure 15. Prophylactic HIV Drug Consumed in Hospital Pharmacy
Figure 16. Global Prophylactic HIV Drug Market: Hospital Pharmacy (2020-2025) & (K Units)
Figure 17. Prophylactic HIV Drug Consumed in Retail Pharmacy
Figure 18. Global Prophylactic HIV Drug Market: Retail Pharmacy (2020-2025) & (K Units)
Figure 19. Prophylactic HIV Drug Consumed in Online Pharmacy
Figure 20. Global Prophylactic HIV Drug Market: Online Pharmacy (2020-2025) & (K Units)
Figure 21. Global Prophylactic HIV Drug Sale Market Share by Application (2024)
Figure 22. Global Prophylactic HIV Drug Revenue Market Share by Application in 2025
Figure 23. Prophylactic HIV Drug Sales by Company in 2025 (K Units)
Figure 24. Global Prophylactic HIV Drug Sales Market Share by Company in 2025
Figure 25. Prophylactic HIV Drug Revenue by Company in 2025 ($ millions)
Figure 26. Global Prophylactic HIV Drug Revenue Market Share by Company in 2025
Figure 27. Global Prophylactic HIV Drug Sales Market Share by Geographic Region (2020-2025)
Figure 28. Global Prophylactic HIV Drug Revenue Market Share by Geographic Region in 2025
Figure 29. Americas Prophylactic HIV Drug Sales 2020-2025 (K Units)
Figure 30. Americas Prophylactic HIV Drug Revenue 2020-2025 ($ millions)
Figure 31. APAC Prophylactic HIV Drug Sales 2020-2025 (K Units)
Figure 32. APAC Prophylactic HIV Drug Revenue 2020-2025 ($ millions)
Figure 33. Europe Prophylactic HIV Drug Sales 2020-2025 (K Units)
Figure 34. Europe Prophylactic HIV Drug Revenue 2020-2025 ($ millions)
Figure 35. Middle East & Africa Prophylactic HIV Drug Sales 2020-2025 (K Units)
Figure 36. Middle East & Africa Prophylactic HIV Drug Revenue 2020-2025 ($ millions)
Figure 37. Americas Prophylactic HIV Drug Sales Market Share by Country in 2025
Figure 38. Americas Prophylactic HIV Drug Revenue Market Share by Country (2020-2025)
Figure 39. Americas Prophylactic HIV Drug Sales Market Share by Type (2020-2025)
Figure 40. Americas Prophylactic HIV Drug Sales Market Share by Application (2020-2025)
Figure 41. United States Prophylactic HIV Drug Revenue Growth 2020-2025 ($ millions)
Figure 42. Canada Prophylactic HIV Drug Revenue Growth 2020-2025 ($ millions)
Figure 43. Mexico Prophylactic HIV Drug Revenue Growth 2020-2025 ($ millions)
Figure 44. Brazil Prophylactic HIV Drug Revenue Growth 2020-2025 ($ millions)
Figure 45. APAC Prophylactic HIV Drug Sales Market Share by Region in 2025
Figure 46. APAC Prophylactic HIV Drug Revenue Market Share by Region (2020-2025)
Figure 47. APAC Prophylactic HIV Drug Sales Market Share by Type (2020-2025)
Figure 48. APAC Prophylactic HIV Drug Sales Market Share by Application (2020-2025)
Figure 49. China Prophylactic HIV Drug Revenue Growth 2020-2025 ($ millions)
Figure 50. Japan Prophylactic HIV Drug Revenue Growth 2020-2025 ($ millions)
Figure 51. South Korea Prophylactic HIV Drug Revenue Growth 2020-2025 ($ millions)
Figure 52. Southeast Asia Prophylactic HIV Drug Revenue Growth 2020-2025 ($ millions)
Figure 53. India Prophylactic HIV Drug Revenue Growth 2020-2025 ($ millions)
Figure 54. Australia Prophylactic HIV Drug Revenue Growth 2020-2025 ($ millions)
Figure 55. China Taiwan Prophylactic HIV Drug Revenue Growth 2020-2025 ($ millions)
Figure 56. Europe Prophylactic HIV Drug Sales Market Share by Country in 2025
Figure 57. Europe Prophylactic HIV Drug Revenue Market Share by Country (2020-2025)
Figure 58. Europe Prophylactic HIV Drug Sales Market Share by Type (2020-2025)
Figure 59. Europe Prophylactic HIV Drug Sales Market Share by Application (2020-2025)
Figure 60. Germany Prophylactic HIV Drug Revenue Growth 2020-2025 ($ millions)
Figure 61. France Prophylactic HIV Drug Revenue Growth 2020-2025 ($ millions)
Figure 62. UK Prophylactic HIV Drug Revenue Growth 2020-2025 ($ millions)
Figure 63. Italy Prophylactic HIV Drug Revenue Growth 2020-2025 ($ millions)
Figure 64. Russia Prophylactic HIV Drug Revenue Growth 2020-2025 ($ millions)
Figure 65. Middle East & Africa Prophylactic HIV Drug Sales Market Share by Country (2020-2025)
Figure 66. Middle East & Africa Prophylactic HIV Drug Sales Market Share by Type (2020-2025)
Figure 67. Middle East & Africa Prophylactic HIV Drug Sales Market Share by Application (2020-2025)
Figure 68. Egypt Prophylactic HIV Drug Revenue Growth 2020-2025 ($ millions)
Figure 69. South Africa Prophylactic HIV Drug Revenue Growth 2020-2025 ($ millions)
Figure 70. Israel Prophylactic HIV Drug Revenue Growth 2020-2025 ($ millions)
Figure 71. Turkey Prophylactic HIV Drug Revenue Growth 2020-2025 ($ millions)
Figure 72. GCC Countries Prophylactic HIV Drug Revenue Growth 2020-2025 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Prophylactic HIV Drug in 2025
Figure 74. Manufacturing Process Analysis of Prophylactic HIV Drug
Figure 75. Industry Chain Structure of Prophylactic HIV Drug
Figure 76. Channels of Distribution
Figure 77. Global Prophylactic HIV Drug Sales Market Forecast by Region (2026-2031)
Figure 78. Global Prophylactic HIV Drug Revenue Market Share Forecast by Region (2026-2031)
Figure 79. Global Prophylactic HIV Drug Sales Market Share Forecast by Type (2026-2031)
Figure 80. Global Prophylactic HIV Drug Revenue Market Share Forecast by Type (2026-2031)
Figure 81. Global Prophylactic HIV Drug Sales Market Share Forecast by Application (2026-2031)
Figure 82. Global Prophylactic HIV Drug Revenue Market Share Forecast by Application (2026-2031)